Oryon Cell Therapies Emerges From Stealth With $21 Million Series A

Oryon Cell Therapies is a clinical-stage biotechnology company developing autologous cell therapies for neurodegenerative disorders, initially focusing on Parkinson's disease.

Co-founded in 2020 by Ole Isacson, M.D. Ph.D., and Nikola Kojic, M.D., Ph.D., the company's technology aims to restore synaptic function and motor control.

Recently, Oryon has closed a new $21 million tranche of its Series A financing, totaling $42 million in funding.

Investors include Neuro.VC, Byers Capital, and others.

The company's initial program focuses on a neuron replacement therapy to restore dopaminergic function in the brains of Parkinson's patients.